EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

Sunday 7th October 2018

Time slot Topic / Title of presentation Chair

9.00 – 11.00 Board meeting

11.00 – 11.30 Arrivals & Welcome coffee

11.30 – 11.50

Welcome & Introduction B. Besse, N.Reguart, J.Remon,

New Board, , Membership status, Calendar and publications/abstracts, Finances

B. Besse, , A-M Dingemans, T. Berghmans

11.50 – 12.20

Protocols in SCLC and Thymic Malignancies:

1417 (REACTION): A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer – B. Besse

1525 (NivoThym): Single-arm, multicenter, phase II study

of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy – N. Girard

B. Besse, Jessica Menis

12.20 – 12.40 Oligometastatic disease consensus: update

A-M Dingemans

12.40 – 13.40

Protocols in early stage, locally advanced and brain metastases NSCLC:

1702 (HALT): Targeted therapy beyond progression with or without dose-intensified radiotHerapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumours – M. Guckenberger, N. Andratschke

1416 (PEARLS): A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS) – M. O’ Brien

J. Edwards, A. Levy, Cécile Le Pechoux

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

1807: Randomized phase II trials of early radiosurgery versus delayed radiosurgery or other salvage treatment (EVER) with either checkpoint inhibition (EVER-IO) or tyrosine kinase inhibitors (EVER-TKI) for the treatment of patients with brain metastases from non-small cell lung cancer (NSCLC) – M. Guckenberger, N. Andratschke

Concept: PRIMALung

13.40 – 14.40 Lunch

14:40 – 15:10 Young Investigators Projects I L. Hendriks, M. Giaj Levra

15.10 – 16.10

Protocols in advanced NSCLC:

1613 (APPLE): Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients - R. Dziadziuszko, J. Remon

1643 (SOLUTION): Randomized phase II study of

durvalumab and tremelimumab combination versus standard of care plus durvalumab following first-line platinum based chemotherapy plus durvalumab in two cohorts of patients with non-squamous and squamous NSCLC – L. Hendriks

08111 (SPLENDOUR): A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC – Final analysis results – B. Hasan

Concepts:

1825 (ALKALINE): Activity of Lorlatinib based on ALK resistance mutations on blood in 2nd or subsequent lines in ALK positive NSCLC patients - A-M Dingemans, L. Mezquita

A phase II randomized, open label, study of nivolumab plus ipilimumab in combination with platinum-based chemotherapy compared with platinum-based chemotherapy, compared with nivolumab plus ipilimumab for the treatment of elderly patients with advanced, metastatic non-small cell lung cancer (NSCLC). - S. Novello, M. Giaj Levra

B. Besse, J. Corral, E. Smit

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

16:10 – 18:10 KEY Lectures

16:10-16:30 The role of the Spanish Medical Oncology Society (SEOM) in the European Oncology Community

Ruth Vera

16:30-16:50 How do I foresee lung cancer treatment in the five years to come Luis Paz-Ares

16.50 – 17:10 Coffee break

17:10-17:30 Is it possible to improve patients’ outcomes in oligometastatic NSCLC with local therapy?

Ramon Rami-Porta

17:30-17:50 PDL-1 vs TMB: do we have a winner? Fernando López-Ríos

17:50-18:10 Clinical applications of liquid biopsy: screening, molecular residual disease and new designs of clinical trials

Rafael López López

18.10 – 19.00 Joint session with Pharma Sponsor

18:10-18:25 Bls early portfolio: focus on NSCLC Dejan Radonjic

18:25-18:40 Tumor DNA Digital NGS in Thoracic malignancies Noemí Reguart

19:00 – 20:30 Free Time

20:30

Dinner at EL VIVERO

Paseo Balmins, s/n

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

Monday 8th October 2018

Time slot Topic / Title of presentation Chair

8.00 – 09.00 Breakfast for young investigators

09.15 – 10.00

TR protocols and projects:

SPECTA: Screening Patients with thoracic tumors for Efficient Clinical Trial Access – B. Besse

IMMUcan project: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts – B. Besse

Concept:

1824-LCG EuroBioradon : European observational study of the indoor radon in non-small cell lung cancer (NSCLC) patients harboring driver molecular alterations – L. Mezquita

S. Novello, F. Fachinetti

10:00 – 10:30 Young Investigators Projects II L. Hendriks, A. Levy

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

10:30 -11:00

Protocols in mesothelioma

1205: EORTC randomized phase II study of pleurectomy/ decortication (P/D) preceded or followed by chemotherapy in patients with early stage malignant pleural mesothelioma – J. Raskin

08112 (NEMO): Nintedanib as maintenance treatment of

malignant pleural mesothelioma: a double-blind randomized phase II study of the EORTC Lung Cancer Group - A. Pochesci

Concepts:

1752 (MESAVEL): Phase II trial in pretreated Malignant pleural MESothelioma with AVELumab in combination with Nintedanib or Chemotherapy - N. Reguart, F. Fachinetti

L. Greillier, G. Pasello

11:00- 11:30 Coffee break

11:30 – 12:30

New proposals

PECATI phase II study: PEmbrolizumab, CArboplatin,

pacliTaxel in thymIc carcinoma – J. Remon

CTLA4 Intratumoral and PDL1 inhibitor Combination in

CBNPC – B. Duchemann

A phase II study of Nivolumab in Large Cell Neuro-Endocrine

Lung Cancer (LCNEC) with PROFICIENT LKB1 – C. Lindsay

Treatment of early-stage NSCLC; current clinical practice in Europe and unrevealing factors influencing decision making;

SABR or resection– K. Hartemink

PIE-trial: PD1/PD-L1 Inhibitor-combinations in EGFR mutant

NSCLC patients progressing after EGFR TKI – G. Pasello

A randomized phase III trial comparing doublet platinum

chemotherapy with or without atezolizumb and bevacizumab in

EGFR mutated patients after failure to effective tyrosin-kinase

inhibitors – A. Ortega

B. Besse, A-M. Dingemans, S. Novello

12.30 – 12.45 Wrap-up & Conclusions B. Besse

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

12.45 – 12.50 End of the meeting B. Besse

13.00 – 14.30 Lunch

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)

EORTC LUNG CANCER GROUP – GROUP MEETING

7, 8th October 2018

Hotel Terramar Sitges Passeig Marítim, 80, 08870 Sitges (Barcelona)

(Vintage room)